Author:
Horvat Ivana,Boban Ana,Zadro Renata,Antolic Margareta Radic,Serventi-Seiwerth Ranka,Roncevic Pavle,Radman Ivo,Sertic Dubravka,Vodanovic Marijo,Pulanic Drazen,Basic-Kinda Sandra,Durakovic Nadira,Zupancic-Salek Silva,Vrhovac Radovan,Aurer Igor,Nemet Damir,Labar Boris
Subject
Cancer Research,Oncology,Hematology
Reference40 articles.
1. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders;Baxter;Lancet,2005
2. Epidemiology of myelofibrosis, essential thrombocythemia, and polycythemia vera in the European Union;Moulard;Eur J Haematol,2014
3. Thrombosis in myeloproliferative disorders: prevalence, prognostic factors, and the role of leukocytes and JAK2 V617F;Tefferi;Semin Thromb Hemost,2007
4. Clinical profile of homozygous JAK2 617V > F mutation in patients with polycythemia vera or essential thrombocythemia;Vannucchi;Blood,2007
5. Bleeding, thrombosis, and anticoagulation in myeloproliferative neoplasms (MPN): analysis from the German SAL-MPN-registry;Kaifie;J Hematol Oncol,2016
Cited by
24 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献